COX-2


Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to COX-2: Cox-1
AcronymDefinition
COX-2Cyclooxygenase 2
References in periodicals archive ?
Other research, however, suggested that most prostate cancers and between 10 and 40 percent of pancreatic tumors don't produce COX-2 and so are called COX-2 negative.
In another study published in Annals of Internal Medicine, the COX-2 inhibitor rofecoxib was compared to indomethacin, confirming that these drugs reduce kidney function.
In the face of pent up demand, coupled with presumably an aggressive physician and a direct-to-consumer marketing campaign by the manufacturer, what can health plans do to prepare for cox-2 inhibitors?
This report includes seven analysis statements, originally published in response to major events in the Cox-2 story between November 2004 and May 2005.
Blatteis, a physiologist at the University of Tennessee College of Medicine in Memphis, has been testing the effects of COX-1 and COX-2 inhibitors on prostaglandin production in guinea pigs with fever.
However 75% believe that COX-2 Inhibitors have an important role in providing greater protection to patients at risk for severe and sometimes life-threatening gastric bleeding associated with long-term use of NSAIDs.
Researchers have shown that, on the biochemical level, Cox-2 chemically alters prostaglandin, a hormonelike compound that stimulates inflammation and cell proliferation.
Flamel has filed a patent with claims on the combination of COX-2 inhibitors with Asacard(R), our Micropump(R) enabled formulation of aspirin, to address the problems of thrombosis observed with patients who are taking COX-2 inhibitors.
Marnett and his colleagues at Vanderbilt synthesized a series of aspirinlike molecules and found APHS to be 60 times more potent than aspirin in reacting with COX-2.
DuBois and his colleagues are trying to figure out how too much COX-2 and prostaglandin cause cancer and how the drugs inhibit this process.
Proving the safety of other Cox-2 inhibitors in long-term use is, therefore, likely to be a difficult task.
This briefing will provide manufacturers, investors, physicians and other industry participants with an overview of the Cox-2 inhibitors markets before and three possible market scenarios after recall.